NAS:XERS (USA)
Business Description
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601
Compare
Compare
Traded in other countries / regions
2B30.Germany
•
0A8E.UK
•
XERS.USA
Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.96 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.43 | |||||
| Debt-to-EBITDA | -1.1 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.11 | |||||
| Beneish M-Score | 143.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | 32.9 | |||||
| 3-Year EPS without NRI Growth Rate | 32.3 | |||||
| 3-Year FCF Growth Rate | 36.6 | |||||
| 3-Year Book Growth Rate | -40.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.13 | |||||
| 9-Day RSI | 58.55 | |||||
| 14-Day RSI | 55.13 | |||||
| 6-1 Month Momentum % | -29.46 | |||||
| 12-1 Month Momentum % | -29.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 2.42 | |||||
| Cash Ratio | 1.99 | |||||
| Days Inventory | 304.19 | |||||
| Days Sales Outstanding | 86.7 | |||||
| Days Payable | 140.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -81.7 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.1 | |||||
| Operating Margin % | -200.19 | |||||
| Net Margin % | -216.74 | |||||
| ROE % | -272.24 | |||||
| ROA % | -63.18 | |||||
| ROIC % | -174.22 | |||||
| ROC (Joel Greenblatt) % | -1956.82 | |||||
| ROCE % | -76.49 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.65 | |||||
| PB Ratio | 2.41 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-EBITDA | -1.87 | |||||
| EV-to-Revenue | 3.73 | |||||
| EV-to-Forward-Revenue | 2.37 | |||||
| EV-to-FCF | -2.13 | |||||
| Earnings Yield (Greenblatt) % | -54.83 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:XERS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 63.683 | ||
| EPS (TTM) ($) | -1.47 | ||
| Beta | 2.27 | ||
| Volatility % | 69.59 | ||
| 14-Day RSI | 55.13 | ||
| 14-Day ATR ($) | 0.11949 | ||
| 20-Day SMA ($) | 1.533 | ||
| 12-1 Month Momentum % | -29.46 | ||
| 52-Week Range ($) | 1.25 - 3.1688 | ||
| Shares Outstanding (Mil) | 135.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xeris Biopharma Holdings Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||